Intellia Therapeutics, Inc.
Intellia Therapeutics is a leading genome editing company focused on the development of proprietary curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The company's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products.
Foresite Capital believes that gene editing has the potential to treat a broad range of diseases not adequately addressed by traditional therapeutic modalities. Intellia has developed a sound business strategy focused on step-wise clinical de-risking, and has validated its platform through key partnerships with Novartis and Regeneron.